Enteris BioPharma Inc., a Boonton-based biotechnology firm and a wholly-owned subsidiary of SWK Holdings Corp., announced it has hired Gary A. Shangold as chief medical officer.
Shangold, who has nearly 30 years of experience in the biopharmaceutical industry, will be responsible for advancing the company’s external and internal programs as well as developing new licensing and partnership opportunities.
“Adding a biopharmaceutical executive of Gary’s caliber so soon after our acquisition by SWK Holdings is a tremendous achievement for Enteris and our mission to be the industry leader in developing oral tablet formulations of peptides and other molecules with low oral bioavailability or permeability,” Brian Zietsman, CEO and president of Enteris.  “Gary brings to Enteris an unmatched blend of executive experience and drug development, regulatory and commercialization expertise, including numerous INDs, NDAs and FDA approvals.”
In addition to his role at Enteris, Shangold currently serves as CEO of InteguRx Therapeutics, a company he founded to develop transdermal pharmaceutical products, and is president of Convivotech, a consultancy to life science firms. Before that, he held several senior roles at large biopharmaceutical firms, including a 10-year span at Johnson & Johnson Pharmaceutical R&D and Serono Labs. He was also the chief medical officer and executive vice president for R&D at Xanodyne Pharmaceuticals and CEO and president of NovaDel Pharma. He also spend a decade in academia, as faculty at The University of Chicago Pritzker School of Medicine and then later at Massachusetts General Hospital and the Harvard School of Medicine.
“I believe that Enteris, with the support of SWK Holdings, is on the cusp of what could be a transformative opportunity,” Shangold said. “Having built a career identifying opportunities and developing drug products that utilize novel formulations and delivery technologies, I believe that Enteris’ Peptelligence platform could hold the key to enhancing myriad drug products and treatment paradigms by enabling the oral delivery of peptides and other difficult-to-dose therapeutics, which, today, can only be administered via injection. I greatly look forward to working with Brian and the Enteris team to cultivate Peptelligence-driven licensing and development partners, while also potentially identifying additional drug delivery technologies that are complementary to Peptelligence and could enable Enteris to target an even wider array of deal opportunities.”
